| | Title | Author(s) | Year | View Count | | 1 |  | Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B | Lai, CL; Shouval, D; Lok, AS; Chang, TT; Cheinquer, H; Goodman, Z; DeHertogh, D; Wilber, R; Zink, RC; Cross, A; Colonno, R; Fernandes, L | 2006 | 408 |
| 2 |  | HBsAg seroclearance in the natural history of chronic hepatitis B infection | Yuen, MF; Lai, CL | 2006 | 77 |
| 3 |  | A new drug for chronic hepatitis B: entecavir | Yuen, RMF; Lai, CL | 2006 | 69 |
| 4 | | Maximal Early Hbv Suppression In Nucleoside-treated Hepatitis B Patients Is Associated With Optimal Virologic And Clinical Efficacy At One Year | Lim, SG; Lai, CL; Thongsawat, S; Wang, Y; Chen, Y; Rasenack, J; Naoumov, N; Chao, G; Brown, N | 2006 | 108 |
| 5 | | Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong | Cheung, TK; Lai, CL; Wong, BCY; Fung, J; Yuen, MF | 2006 | 102 |
| 6 | | Hepatitis B virus with primary resistance to adefovir [11] | Chang, TT; Lai, CL | 2006 | 138 |
| 7 | | Telbivudine: a new treatment option in the management of chronic hepatitis B | Fung, J; Lai, CL; Yuen, MF | 2006 | 149 |
| 8 | | T1653 mutation in the box α increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C Infection | Ito, K; Tanaka, Y; Orito, E; Sugiyama, M; Fujiwara, K; Sugauchi, F; Kato, T; Tokita, H; Izumi, N; Kato, M; Yuen, MF; Lai, CL; Gish, RG; Ueda, R; Mizokemi, M | 2006 | 47 |
| 9 | | Authors' reply [5] | Yuen, MF; Lai, CL | 2006 | 26 |
| 10 | | Entecavir: A viewpoint by Ching-Lung Lai and Man-Fung Yuen | Lai, CL; Yuen, MF | 2006 | 30 |
| 11 | | Overcoming the problem of chronic hepatitis B | Fung, J; Lai, CL; Yuen, MF | 2006 | 31 |
| 12 | | Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma | Wong, DKH; Yuen, MF; Poon, RTP; Yuen, JCH; Fung, J; Lai, CL | 2006 | 102 |
| 13 | | Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment | Yuen, MF; Sablon, E; Libbrecht, E; Van De Velde, H; Wong, DKH; Fung, J; Wong, BCY; Lai, CL | 2006 | 38 |
| 14 | | Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: A 1-year prospective study | Yuen, MF; Tam, S; Fung, J; Wong, DKH; Wong, BCY; Lai, CL | 2006 | 83 |
| 15 | | One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels | Wong, DKH; Yuen, MF; Ngai, VWS; Fung, J; Lai, CL | 2006 | 82 |
| 16 | | A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B | Lai, CL; Leung, N; Teo, EK; Tong, M; Wong, F; Hann, HW; Han, S; Poynard, T; Myers, M; Chao, G; Lloyd, D; Brown, NA | 2005 | 1,110 |
| 17 | | The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B | Yuan, HJ; Yuen, MF; Wong, DKH; Sablon, E; Lai, CL | 2005 | 108 |
| 18 | | Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B | Yuan, HJ; Yuen, MF; Wong, DKH; Sum, SM; Sablon, E; Ng, IOL; Lai, CL | 2005 | 96 |
| 19 | | Serological markers of liver cancer | Yuen, MF; Lai, CL | 2005 | 89 |
| 20 | | Determinants for the occurrence of acute exacerbation of hepatitis B virus infection in Chinese patients after HBeAg seroclearance | Yuan, HJ; Yuen, MF; Wong, DKH; Sum, SM; Doutreloigne, J; Sablon, E; Lai, CL | 2005 | 251 |
|
